Is it too late to buy rapid risers ARM Holdings plc, WPP plc ord 10p and Hikma Pharmaceuticals plc?

Edward Sheldon looks at whether it’s too late to buy fast movers ARM Holdings plc (LON: ARM), WPP plc ord 10p (LON: WPP) and Hikma Pharmaceuticals plc (LON: HIK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

After the market-wide Brexit carnage on the morning of 24 June, I’ve been quite surprised by the rapid rebounds in many FTSE 100 stocks. Today I’m looking at three popular UK growth companies and examining whether it’s too late to jump on board these gravity defying stocks.

Tech king

After trading as low as 970p on 24 June, ARM Holdings (LSE: ARM) has spiked to 1,200p, a 24% gain.  At that price ARM is trading on a current P/E ratio of 49, which falls to 33 on next year’s earnings. Is that too much to pay?

While a P/E ratio of 49 might seem high, on a relative basis it’s actually low for ARM. The tech giant has traditionally traded on high multiples thanks to its impressive growth record, with its P/E ratio climbing as high as 143 in early 2014 and averaging 59 over the last 10 years on a quarterly basis.

While analysts have concerns over slowing smartphone growth, I believe the long term growth story is still intact at ARM. The company is broadening its revenue base to focus on networking, servers and the Internet of Things and these areas should offset any weakness in smartphone chip revenues.  

ARM has grown its earnings at an annualised rate of 29% over the last five years and with the city forecasting revenue growth of 20% and 13% for the next two years, long term investors should continue to be rewarded.

Blue sky territory

Advertising giant WPP (LSE: WPP) has rebounded 13% since its post Brexit lows and is now trading in blue sky territory, having surpassed its all-time highs set in April.

As advertising companies are often seen as proxies for global growth, I wasn’t expecting to see such a rise from WPP with the current economic uncertainty surrounding the UK and Europe. However WPP has strong exposure to the US and fast growing emerging markets, and this has clearly appealed to investors.

As a WPP shareholder I’m not complaining about the stock’s recent performance as the company has been one of the better performers in my portfolio since I bought it, showing gains of almost 30% in less than a year. But would I buy more WPP shares at the current price?

Trading on a P/E ratio of 15 times next year’s earnings, WPP doesn’t look particularly expensive, however looking at the share price chart it’s clear to see that it’s prone to peaks and troughs. For this reason, I’ll be waiting for another dip in the share price before I add to my position.

Fast gains

Hikma Pharmaceuticals (LSE: HIK) has been on my watch list for a while now and I’m kicking myself that I didn’t buy a small position during the Brexit chaos as the stock has risen an incredible 38% since then.

I’m very bullish on the long-term prospects for Hikma as after acquiring Bedford Laboratories and Roxane Laboratories in the last two years, the healthcare company is poised to launch many new drugs in the near future. Furthermore, with a high proportion of its sales in the US, Hikma should benefit from weaker sterling.

However, as with WPP, I’ll be waiting for a pullback before buying-in. Patience is everything in this game and I’m sure there will be a better opportunity to buy Hikma in the future at a lower price.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon owns shares in WPP. The Motley Fool UK has recommended ARM Holdings and Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing For Beginners

3 top Vanguard ETFs to consider for an ISA or SIPP in 2025

Looking for core holdings for an investment account or SIPP? These Vanguard ETFs could be worth considering, says Edward Sheldon.

Read more »

Investing Articles

Are these the best 10 UK shares to consider buying and holding in 2025?

Here are the best-performing UK shares for the second half of 2024. Can they maintain their upward trajectory? Zaven Boyrazian…

Read more »

Investing Articles

Will the stock market crash in 2025?

Some think there could be a stock market crash next year. Should investors heed the warnings or ignore them? Here’s…

Read more »

Investing Articles

Is this penny stock on track for an explosive recovery in 2025?

This penny stock skyrocketed 1,400% in early 2024! But will the group’s latest operational progress send the shares even higher…

Read more »

Investing Articles

Here are 5 of the most popular passive income stocks investors are buying

These are the most bought passive income stocks in December, but are they truly good investments? Zaven Boyrazian looks at…

Read more »

Investing Articles

Where can the BAE Systems share price go in 2025? Let’s ask the experts

The BAE Systems share price has had a strong year in 2024, but it's started slipping back a bit as…

Read more »

Investing Articles

Fancy a £20k+ passive income? Consider buying FTSE 100 and FTSE 250 shares!

Investing in UK blue-chip shares from the FTSE and elsewhere can be a great way to build wealth. Here's one…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

I’ve just bought more of this sinking FTSE 100 share! Here’s why

Looking for long-term share price gains and dividend growth? Check out this FTSE 100 share our writer's bought in recent…

Read more »